Showing 4071-4080 of 6662 results for "".
- Hydrogen Peroxide 40% Less Cytotoxic Than Cryotherapy: Studyhttps://practicaldermatology.com/news/hydrogen-peroxide-40-less-cytotoxic-than-cryotherapy-study/2457822/Hydrogen peroxide topical solution 40% (Eskata, Aclaris) is less cytotoxic to living cells and less damaging to melanocytes than cryosurgery, according to a new study led by Adam Friedman, MD, associate professor of dermatology at the GW School of Medicine and Health Sciences. <
- Skin May Lose Long-Standing Title of Body's Largest Organ to the “Interstitium”https://practicaldermatology.com/news/skin-may-lose-long-standing-title-of-bodys-largest-organ-to-the-interstitium/2457823/The skin has always been considered the largest organ in the body, but it may have some competition -- the newly defined interstitium. The Feinstein Institute for Medical Research researcher Petros Constantinos Benias, MD, and collaborator
- FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposurehttps://practicaldermatology.com/news/fda-approves-label-update-for-cimzia-addressing-low-risk-of-fetal-exposure/2457828/The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to breast milk fr
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- Hair Loss Drug May Boost Heart Healthhttps://practicaldermatology.com/news/hair-loss-drug-may-boost-heart-health/2457833/Oral minoxidil may improve blood flow to the brain, lower blood pressure and increase elasticity in the blood vessels, according to a new study in mice. The article is published in the American Journal of Physiology&mdash
- Aclaris Therapeutics Receives US Patent Covering a JAK Inhibitor for Treating Hair Loss Disordershttps://practicaldermatology.com/news/aclaris-therapeutics-receives-us-patent-covering-a-jak-inhibitor-for-treating-hair-loss-disorders/2457840/The United States Patent and Trademark Office (USPTO) issued US Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders. This newly allowed patent is owned by The Trustees of Columbia Unive
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- Research Shines Light on Why People Experience AD in Winterhttps://practicaldermatology.com/news/research-shines-light-on-why-people-experience-ad-in-winter/2457845/New research shows that the skin barrier is affected by climatic and seasonal changes. In tests of skin on 80 adults, the levels of breakdown products of filaggrin changed between winter and summer on the cheeks and h
- Sensus Healthcare Launches New Line of Laser Systems for Clinical and Aesthetic Dermatologyhttps://practicaldermatology.com/news/sensus-healthcare-launches-new-line-of-laser-systems-for-clinical-and-aesthetic-dermatology/2457846/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to complement its existing superficial radiation therapy (SRT) system, which is used for non-invasive treatment of non-melanoma skin cancers and keloids. T
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil